公开(公告)号：US20160297892A1

公开(公告)日：2016-10-13

申请号：US15033835

申请日：2014-11-07

Applicant: NOVO NORDISK A/S

Inventor： Helle Heibroch Petersen ,  Mette Brunsgaard Hermit ,  Heidi Lindgreen Holmberg ,  Berit Olsen Krogh ,  Kristian Kjaergaard ,  Mette Dahl Andersen ,  Rune Salbo ,  Emily Waters ,  Lisbeth Moreau Andersen ,  Kristoffer Winther Balling

IPC: C07K16/36

CPC classification number: C07K16/36 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/522 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76

Abstract: The present invention relates to pro-coagulant human Protein S inhibitors, such as antibodies or antigen-binding fragments thereof that can be administered subcutaneously as prophylactic treatment for haemophilia patients regardless of inhibitor status and without interfering with non-coagulant functions of Protein S.

Abstract translation: 本发明涉及促凝血人蛋白S抑制剂，例如抗体或其抗原结合片段，其可以作为血友病患者的预防性治疗皮下施用，而不管抑制剂状态如何，并且不干扰蛋白S的非凝血功能。

公开(公告)号：US20150344576A1

公开(公告)日：2015-12-03

申请号：US14829170

申请日：2015-08-18

Applicant: Novo Nordisk A/S - Novo Alle ,  Innate Pharma S.A.S. ,  University of Genoa

Inventor： Alessandro Moretta ,  Mariella Della Chiesa ,  Pascale Andre ,  Laurent Gauthier ,  Francois Romagne ,  Peter Andreas Nicolai Reumert Wagtmann ,  Ivan Svendsen ,  Stefan Zahn ,  Anders Svensson ,  Matthias Thorolfsson ,  Soren Berg Padkaer ,  Kristian Kjaergaard ,  Pieter Johannes Louis Spee ,  Michael Wilken

IPC: C07K16/28

CPC classification number: C07K16/42 ,  C07K16/28 ,  C07K16/2803 ,  C07K2299/00 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.

Abstract translation: 描述了用于调节受试者的免疫应答的组合物和方法。 更具体地，描述了调节NK细胞活性并允许哺乳动物受试者中NK细胞细胞毒性增强的抗体，以及具有与人单克隆抗体1-7F9或1-4F1类似的抗原结合特性的抗体。 还描述了这种抗体的片段和衍生物，以及包含其的药物组合物及其用途，特别是用于治疗，以增加受试者的NK细胞活性或细胞毒性。

公开(公告)号：US20150191547A1

公开(公告)日：2015-07-09

申请号：US14659045

申请日：2015-03-16

Applicant: Novo Nordisk A/S - Novo Alle ,  Innate Pharma S.A.S. ,  University of Genoa

Inventor： Alessandro Moretta ,  Mariella Della Chiesa ,  Pascale Andre ,  Laurent Gauthier ,  Francois Romagne ,  Peter Andreas Nicolai Reumert Wagtmann ,  Ivan Svendsen ,  Stefan Zahn ,  Anders Svensson ,  Matthias Thorolfsson ,  Soren Berg Padkaer ,  Kristian Kjaergaard ,  Pieter Johannes Louis Spee ,  Michael Wilken

IPC: C07K16/42

CPC classification number: C07K16/42 ,  C07K16/28 ,  C07K16/2803 ,  C07K2299/00 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.

公开(公告)号：US20130287770A1

公开(公告)日：2013-10-31

申请号：US13936486

申请日：2013-07-08

Applicant: INNATE PHARMA S.A.S. ,  NOVO-NORDISK A/S - NOVO ALLE

Inventor： Alessandro Moretta ,  Mariella Della Chiesa ,  Pascale Andre ,  Laurent Gauthier ,  Francois Romagne ,  Peter Andreas Nicolai Reumert Wagtmann ,  Ivan Svendsen ,  Stefan Zahn ,  Anders Svensson ,  Matthias Thorolfsson ,  Soren Berg Padkaer ,  Kristian Kjaergaard ,  Pieter Johannes Loius Spee ,  Milchael Wilken

IPC: C07K16/28

CPC classification number: C07K16/42 ,  C07K16/28 ,  C07K16/2803 ,  C07K2299/00 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.

Abstract translation: 描述了用于调节受试者的免疫应答的组合物和方法。 更具体地，描述了调节NK细胞活性并允许在哺乳动物受试者中增强NK细胞细胞毒性的人抗体，以及具有与人单克隆抗体1-7F9或1-4F1类似的抗原结合特性的抗体。 还描述了这种抗体的片段和衍生物，以及包含其的药物组合物及其用途，特别是用于治疗，以增加受试者的NK细胞活性或细胞毒性。

公开(公告)号：US12116408B2

公开(公告)日：2024-10-15

申请号：US17380404

申请日：2021-07-20

Applicant: Novo Nordisk A/S

Inventor： Anette Henriksen ,  Kristian Kjaergaard ,  Vibeke Westphal Stennicke ,  Charlotte Wiberg

IPC: C07K16/28

CPC classification number: C07K16/2803 ,  C07K2299/00 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2317/94

Abstract: Antibodies that are capable of specifically binding and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils with both good affinity and low viscosity at clinically relevant concentrations are described. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.

公开(公告)号：US11072654B2

公开(公告)日：2021-07-27

申请号：US16203327

申请日：2018-11-28

Applicant: Novo Nordisk A/S

Inventor： Anette Henriksen ,  Kristian Kjaergaard ,  Vibeke Westphal Stennicke ,  Charlotte Wiberg

IPC: C07K16/28

Abstract: Antibodies that are capable of specifically binding and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils with both good affinity and low viscosity at clinically relevant concentrations are described. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.

公开(公告)号：US20170073421A1

公开(公告)日：2017-03-16

申请号：US15341550

申请日：2016-11-02

Applicant: Novo Nordisk A/S

Inventor： Kristian Kjaergaard ,  Soeren Lund ,  Stefan Zahn ,  Louise H. Zeuthen ,  Anker J. Hansen

IPC: C07K16/28

CPC classification number: C07K16/2896 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.

Abstract translation: 本发明涉及识别人C5a受体的人抗体。 通过结合C5aR，抗体抑制C5a信号传导，从而抑制促炎信号。 基于C5a及其受体在炎症刺激中的作用，本发明进一步涉及所述人类抗C5aR抗体的治疗用途，特别是涉及免疫学疾病的治疗。

公开(公告)号：US20240218076A1

公开(公告)日：2024-07-04

申请号：US18536032

申请日：2023-12-11

Applicant: Novo Nordisk A/S

Inventor： Kristian Kjaergaard ,  Soeren Lund ,  Stefan Zahn ,  Louise H. Zeuthen ,  Anker J. Hansen

IPC: C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2896 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.

公开(公告)号：US10882916B2

公开(公告)日：2021-01-05

申请号：US16443736

申请日：2019-06-17

Applicant: Novo Nordisk A/S

Inventor： Kristian Kjaergaard ,  Soeren Lund ,  Stefan Zahn ,  Louise H. Zeuthen ,  Anker J. Hansen

IPC: A61K39/395 ,  C07K16/28 ,  A61K39/00

Abstract: The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.

公开(公告)号：US08981065B2

公开(公告)日：2015-03-17

申请号：US13936486

申请日：2013-07-08

Applicant: Novo Nordisk A/S—Novo Alle ,  Innate Pharma S.A.S. ,  University of Genoa

Inventor： Alessandro Moretta ,  Mariella Della Chiesa ,  Pascale Andre ,  Laurent Gauthier ,  Francois Romagne ,  Peter Andreas Nicolai Reumert Wagtmann ,  Ivan Svendsen ,  Stefan Zahn ,  Anders Svensson ,  Matthias Thorolfsson ,  Soren Berg Padkaer ,  Kristian Kjaergaard ,  Pieter Johannes Louis Spee ,  Michael Wilken

IPC: C12P21/08 ,  C07K16/00 ,  C07K16/28

CPC classification number: C07K16/42 ,  C07K16/28 ,  C07K16/2803 ,  C07K2299/00 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.

Abstract translation: 描述了用于调节受试者的免疫应答的组合物和方法。 更具体地，描述了调节NK细胞活性并允许在哺乳动物受试者中增强NK细胞细胞毒性的人抗体，以及具有与人单克隆抗体1-7F9或1-4F1类似的抗原结合特性的抗体。 还描述了这种抗体的片段和衍生物，以及包含其的药物组合物及其用途，特别是用于治疗，以增加受试者的NK细胞活性或细胞毒性。